Huntingtons Disease Treatment Market
- 2026 年市場規模
- USD 766 Mn
- 2033 年預估規模
- USD 4,197 Mn
- 年複合成長率 CAGR
- 23.8%
以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。
授權報價
| Single User Price | $4,500 USD |
| Enterprise License | $10,000 USD |
完整報告名稱與涵蓋範圍
Huntingtons Disease Treatment Market, By Drug Type (Tetrabenazine, Deutetrabenazine, and Other Drug Type), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)
報告摘要
The Huntington’s Disease Treatment Market is estimated to be valued at USD 766 Mn in 2026 and is expected to reach USD 4,197 Mn by 2033, exhibiting a compound annual growth rate (CAGR) of 23.8% from 2026 to 2033. The market is witnessing strong expansion driven by the increasing prevalence of Huntington’s disease, rising adoption of genetic testing and early diagnosis, growing investment in gene and RNA-based therapies, and rapid advancements in neurodegenerative disorder research and precision medicine approaches.
Huntington’s disease is a progressive, inherited neurodegenerative disorder characterized by motor dysfunction (notably chorea), cognitive decline, and psychiatric disturbances. With no curative therapy currently available, treatment remains largely symptomatic, creating sustained demand for pharmacological and emerging disease-modifying solutions. The growing pipeline of HTT-lowering therapies, including antisense oligonucleotides (ASOs), siRNA-based drugs, and gene therapies, is expected to transform the treatment landscape over the forecast period.
Market Dynamics
The Huntington’s Disease Treatment Market is evolving rapidly due to a combination of clinical, technological, and regulatory factors. A key growth driver is the increasing disease burden and improved diagnostic rates enabled by genetic testing, which allows early identification of at-risk individuals even before symptom onset. This is significantly expanding the treated patient pool and supporting long-term therapy adoption.
Another major driver is the strong pipeline of disease-modifying therapies targeting the mutant huntingtin (HTT) protein. Advancements in RNA interference, gene silencing technologies, and viral vector-based gene therapies are shifting the market focus from purely symptomatic management toward potential disease modification. Increasing clinical trial activity and regulatory incentives for orphan diseases are further accelerating drug development.
The high cost and complexity of Huntington’s disease management, including long-term neurological monitoring and psychiatric care, continue to reinforce hospital-based treatment models. Additionally, the rising prevalence of neurodegenerative disorders globally and expanding awareness among healthcare providers are contributing to sustained market growth.
However, the market faces challenges such as the lack of curative therapies, high development costs of gene therapies, and complex central nervous system (CNS) drug delivery barriers, including limited blood–brain barrier penetration. Despite these constraints, regulatory fast-track pathways and breakthrough therapy designations are encouraging innovation and investment in the space.
Key Features of the Study
• This report provides in-depth analysis of the Huntington’s Disease Treatment Market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the Huntington’s Disease Treatment Market based on the following parameters – company highlights, service portfolio, key developments, financial performance, and strategies
• Key companies covered as a part of this study include Valeant Pharmaceuticals International Inc., Alnylam Pharmaceuticals Inc., Ceregene Inc., Lundbeck, Prana Biotechnology Limited, Teva Pharmaceutical Industries Ltd., Cortex Pharmaceuticals Inc., Vertex Pharmaceuticals Incorporated, Auspex Pharmaceuticals, SOM Biotech, GlaxoSmithKline, Siena Biotech, Raptor Pharmaceutical, Pfizer limited, Palobiofarma S.L, Omeros and Ipsen.
• Insights from this report would allow marketers and management authorities to make informed decisions regarding future service innovations, market expansion, and strategic partnerships
• The Huntington’s Disease Treatment Market report caters to various stakeholders including investors, service providers, pharmaceutical companies, regulatory bodies, and financial analysts
• Stakeholders would benefit from structured analytical frameworks and strategy matrices used in evaluating the Huntington’s Disease Treatment Market
Market Segmentation
• By Drug Type (Revenue, USD Mn, 2021-2033)
o Tetrabenazine
o Deutetrabenazine
o Other Drug Type
• By Distribution Channel (Revenue, USD Mn, 2021-2033)
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
• By Region (Revenue, USD Mn, 2021-2033)
o North America
U.S.
Canada
o Latin America
Brazil
Mexico
Argentina
Rest of Latin America
o Europe
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
o Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
o Middle East
GCC
Israel
Rest of Middle East
o Africa
South Africa
Central Africa
North Africa
• Key Players
o Valeant Pharmaceuticals International Inc.
o Alnylam Pharmaceuticals Inc.
o Ceregene Inc.
o Lundbeck
o Prana Biotechnology Limited
o Teva Pharmaceutical Industries Ltd.
o Cortex Pharmaceuticals Inc.
o Vertex Pharmaceuticals Incorporated
o Auspex Pharmaceuticals
o SOM Biotech
o GlaxoSmithKline (GSK)
o Siena Biotech
o Raptor Pharmaceutical
o Pfizer Limited
o Palobiofarma S.L
o Omeros Corporation
o Ipsen
目錄 Table of Contents
Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
Market Definition and Scope
o Executive Summary
Market Snapshot, By Drug Type
Market Snapshot, By Distribution Channel
Market Snapshot, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
Drivers
Restraints
Market Opportunities
o Impact Analysis
o Market Trends
o Key Developments
o Product Approval
o Collaboration/Merge/Acquisition
o Regulatory Landscape
o PEST Analysis
o Porter’s Five Forces Analysis
o Epidemiology
o Robust Pipeline Analysis
4. Global Huntington’s Disease Treatment Market, By Drug Type, 2021 – 2033, (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022– 2033
Segment Trends
o Tetrabenazine
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Mn)
o Deutetrabenazine
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Mn)
o Other Drug Type
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Mn)
5. Global Huntington’s Disease Treatment Market, By Distribution Channel, 2021 – 2033, (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 – 2033
Segment Trends
o Hospital Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Mn)
o Retail Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Mn)
o Online Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Mn)
6. Global Huntington’s Disease Treatment Market, By Region, 2021 – 2033, (USD Mn)
o Introduction
Market Share Analysis, By Region, 2026 and 2033 (%)
Y-o-Y Growth Analysis, For Regions, 2022–2033
Regional Trends
o North America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Mn)
o U.S.
o Canada
o Latin America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Mn)
o Brazil
o Mexico
o Argentina
o Rest of Latin America
o Europe
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Mn)
o U.K.
o Germany
o Italy
o France
o Spain
o Russia
o Rest of Europe
o Asia Pacific
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Mn)
o China
o India
o Japan
o ASEAN
o Australia
o South Korea
o Rest of Asia Pacific
o Middle East
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Mn)
o GCC
o Israel
o Rest of Middle East
o Africa
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Mn)
o North Africa
o Central Africa
o South Africa
7. Competitive Landscape
o Heat Map Analysis
o Market Share Analysis
o Company Profile
Valeant Pharmaceuticals International Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Alnylam Pharmaceuticals Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Ceregene Inc. (acquired by Sangamo Therapeutics)
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Lundbeck
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Prana Biotechnology Limited
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Teva Pharmaceutical Industries Ltd.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Cortex Pharmaceuticals Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Vertex Pharmaceuticals Incorporated
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Auspex Pharmaceuticals
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
SOM Biotech
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
GlaxoSmithKline (GSK)
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Siena Biotech
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Raptor Pharmaceutical
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Pfizer Limited
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Palobiofarma S.L
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Omeros Corporation
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Ipsen
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
o Analyst Views
8. Section
o References
o Research Methodology
o About Us
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們